What internist can do for the patient after the ischemic stroke

Czech version

Authors: Miroslav Škorňa
Authors‘ workplace: Neurologická klinika LF MU a FN Brno
Published in: Vnitř Lék 2021; 67(1): 7-14
Category: Main Topic

Overview

Stroke is frequent disease especially in older age. It is complex multidisciplinary issue and the internist plays very important role in the care of the stroke patients. Recurrent stroke is often disabling. Therefor the early and proper implementation of the effective secondary prevention is essential. This review presents basic information about the aetiology, diagnostic assessment and the secondary prevention of the ischemic stroke.

Keywords:

troke – aetiology – secondary prevention

Sources

1. Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A et al. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013; 44(7): 2064–2089.

2. Škoda O, Herzig R, Mikulík R, Neumann J, Václavík D, Bar M et al. Klinický standard pro diagnostiku a léčbu pacientů s ischemickou cévní mozkovou příhodou a s tranzitorní ischemickou atakou – verze 2016. Cesk Slov Neurol N. 2016; 79/112(3): 351–363.

3. Škorňa M, Neumann J, Peška S, Mikulík R. Management tranzitorní ischemické ataky a minor stroke. Cesk Slov Neurol N. 2016; 79/112(2): 178–187.

4. Coupland AP, Thapar A, Qureshi MI, Jenkins H, Davies AH. The definition of stroke. JR Soc Med. 2017; 110(1): 9–12.

5. Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, Feldmann E et al. Defini‑ tion and evaluation of transient ischemic attack: a scientific statement for healthca‑ re professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke. 2009; 40(6): 2276–2293.

6. Sedova P, Brown RD, Zvolsky M, Kadlecova P, Bryndziar T, Kubelka T et al. Incidence of Hospitalized Stroke in the Czech Republic: The National Registry of Hospitalized Patients. J Stroke Cerebrovasc, DiS. 2017; 26(5): 979–986.

7. Bruthans J. Epidemiologie a prognóza cévních mozkových příhod. 2009; 19(2).

8. Coutts SB, Modi J, Patel SK, Aram H, Demchuk AM, Goyal M et al. What causes disability after transient ischemic attack and minor stroke?: Results from the CT and MRI in the Triage of TIA and minor Cerebrovascular Events to Identify High Risk Patients (CATCH) Study. Stroke. 2012; 43(11): 3018–3022.

9. Ay H, Furie KL, Singhal A, Smith WS, Sorensen AG, Koroshetz WJ. An evidence‑based causative classification system for acute ischemic stroke. Ann Neurol. 2005; 58(5): 688–697.

10. Tomek A. Základní algoritmus vyšetření etiologie ischemické cévní mozkové příhody. Neurol praxi. 2019; 20(1): 12–16.

11. Sposato LA, Cipriano LE, Saposnik G, Ruíz Vargas E, Riccio PM, Hachinski V. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta‑analysis. Lancet Neurol. 2015; 14(4): 377–387.

12. Kimura K, Minematsu K, Yamaguchi T, (J‑MUSIC) JMSIC. Atrial fibrillation as a predictive factor for severe stroke and early death in 15,831 patients with acute ischaemic stroke. J Neurol Neurosurg Psychiatry. 2005; 76(5): 679–683.

13. Nouh A, Hussain M, Mehta T, Yaghi S. Embolic Strokes of Unknown Source and Cryp‑ togenic Stroke: Implications in Clinical Practice. Front Neurol. 2016; 7: 37.

14. Šaňák D, Hutyra M, Král M, Špaček M, Bártková A. Soumrak kryptogenní ischemické CMP – kardioembolizace je nejčastější příčina. Cesk Slov Neurol N. 2018; 81/114(3): 290–297.

15. Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O‘Donnell MJ et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014; 13(4): 429–438.

16. Hart RG, Catanese L, Perera KS, Ntaios G, Connolly SJ. Embolic Stroke of Undetermined Source: A Systematic Review and Clinical Update. Stroke. 2017; 48(4): 867-72.

17. Tomek A, Olšerová A. Embolický iktus z neurčeného zdroje. Neurol praxi. 2019; 20(1): 28–32.

18. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström‑Lundqvist C et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio‑Thoracic Surgery (EACTS). Eur Heart J. 2020.

19. Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014; 370(26): 2467–2477.

20. Wachter R, Gröschel K, Gelbrich G, Hamann GF, Kermer P, Liman J et al. Holter‑electrocardiogram‑monitoring in patients with acute ischaemic stroke (Find‑AF. Lancet Neurol. 2017; 16(4): 282–290.

21. Brachmann J, Morillo CA, Sanna T, Di Lazzaro V, Diener HC, Bernstein RA, et al. Uncovering Atrial Fibrillation Beyond Short‑Term Monitoring in Cryptogenic Stroke Patients: Three‑Year Results From the Cryptogenic Stroke and Underlying Atrial Fibrillation Trial. Circ Arrhythm Electrophysiol. 2016; 9(1): e003333.

22. Šaňák D, Tomek A, Bar M, Herzig R, Mikulík R, Neumann J et al. Stanovisko Výboru Cerebrovaskulární sekce České neurologické společnosti ČLS JEP k dlouhodobému holte‑ rovskému EKG monitoringu u pacientů s ischemickou cévní mozkovou příhodou. Cesk Slov Neurol N. 2018; 81/114(5): 607.

23. Ricci B, Chang AD, Hemendinger M, Dakay K, Cutting S, Burton T, et al. A Simple Score That Predicts Paroxysmal Atrial Fibrillation on Outpatient Cardiac Monitoring after Embolic Stroke of Unknown Source. J Stroke Cerebrovasc, DiS. 2018; 27(6): 1692–1696.

24. Li YG, Bisson A, Bodin A, Herbert J, Grammatico‑Guillon L, Joung B, et al. C 2 HEST Score and Prediction of Incident Atrial Fibrillation in Poststroke Patients: A French Nationwide Study. J Am Heart Assoc. 2019; 8(13): e012546.

25. Germain DP. Fabry disease. Orphanet J Rare, DiS. 2010; 5: 30.

26. Namdar M. Electrocardiographic Changes and Arrhythmia in Fabry Disease. Front Cardiovasc Med. 2016; 3: 7.

27. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014; 45(7): 2160–2236.

28. Magerová H. Indikace antitrombotické terapie v sekundární prevenci ischemické CMP. Neurol praxi. 2019; 20(1): 17–20.

29. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non‑vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018; 39(16): 1330–1393.

30. Saposnik G, Barinagarrementeria F, Brown RD, Bushnell CD, Cucchiara B, Cushman M, et al. Diagnosis and management of cerebral venous thrombosis: a statement for he‑ althcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011; 42(4): 1158–1192.

31. Ntaios G, Papavasileiou V, Diener HC, Makaritsis K, Michel P. Nonvitamin‑K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: An updated systematic review and meta‑analysis of randomized controlled trials. Int J Stroke. 2017; 12(6): 589–596.

32. Diener HC, Aisenberg J, Ansell J, Atar D, Breithardt G, Eikelboom J et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non‑valvular atrial fibrillation: part 1. Eur Heart J. 2017; 38(12): 852–859.

33. Diener HC, Aisenberg J, Ansell J, Atar D, Breithardt G, Eikelboom J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non‑valvular atrial fibrillation: part 2. Eur Heart J. 2017; 38(12): 860–868.

34. Osmancik P, Herman D, Neuzil P, Hala P, Taborsky M, Kala P, et al. Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High‑Risk Patients With Atrial Fibrillation. J Am Coll Cardiol. 2020; 75(25): 3122–3135.

35. Mas JL, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, et al. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke. N Engl J Med. 2017; 377(11): 1011–1021.

36. Derdeyn CP, Chimowitz MI, Lynn MJ, Fiorella D, Turan TN, Janis LS et al. Aggressive medical treatment with or without stenting in high‑risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet. 2013.

37. Wang Y, Johnston SC. Clopidogrel with aspirin in minor stroke or transient ischemic attack. N Engl J Med. 2013; 369(14): 1376–1377.

38. Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ et al. Clopidogrel and Aspirin in Acute Ischemic Stroke and High‑Risk TIA. N Engl J Med. 2018; 379(3): 215–225.

39. Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S et al. Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. N Engl J Med. 2020; 383(3): 207–217.

40. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. New England Journal of Medicine. 2017; 377(14): 1319–1330.

41. Sharma M, Hart RG, Connolly SJ, Bosch J, Shestakovska O, Ng KKH et al. Stroke Outcomes in the COMPASS Trial. Circulation. 2019; 139(9): 1134–1145.

42. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001; 345(20): 1444–1451.

43. Longstreth WT, Jr., Kronmal RA, Thompson JL, Christenson RH, Levine SR, Gross R et al. Amino terminal pro‑B-type natriuretic peptide, secondary stroke prevention, and choice of antithrombotic therapy. Stroke. 2013; 44(3): 714–719.

44. Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD et al. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. N Engl J Med. 2018; 378(23): 2191–201.

45. Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S et al. Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. N Engl J Med. 2019; 380(20): 1906–1917.

46. Healey JS, Gladstone DJ, Swaminathan B, Eckstein J, Mundl H, Epstein AE et al. Recu‑ rrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial. JAMA Neurol. 2019; 76(7): 764–773.

47. Kamel H, Longstreth WT, Jr., Tirschwell DL, Kronmal RA, Broderick JP, Palesch YY et al. The AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke randomized trial: Rationale and methods. Int J Stroke. 2019; 14(2): 207–214.

48. Geisler T, Poli S, Meisner C, Schreieck J, Zuern CS, Nägele T et al. Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design. Int J Stroke. 2017; 12(9): 985–990.